Bayer and Veracyte today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with...
Read More »Bayer and Neogenomics to provide RNA sequencing-based testing for NTRK gene fusion at no cost for people living with advanced thyroid and colorectal cancers
Bayer today announced the launch of Test4TRK™ program in collaboration with NeoGenomics, Inc. to offer genomic cancer testing for NTRK gene fusions at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic...
Read More »New studies demonstrate value of RNA sequencing in thyroid cancer
Veracyte, Inc. today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic alterations that are targeted by newly available...
Read More »RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its Afirma® Xpression Atlas (XA) genomic test, which is used to help guide surgery and treatment decisions for patients with likely or confirmed ...
Read More »